Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Klinikum der Universität München
Múnich, AlemaniaPublicacions en col·laboració amb investigadors/es de Klinikum der Universität München (88)
2024
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
-
EUSOMA quality indicators for non-metastatic breast cancer: An update
European Journal of Cancer, Vol. 198
-
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457
-
Heparin dosing in patients with Impella-supported cardiogenic shock
International Journal of Cardiology, Vol. 399
-
Patient-Reported Outcomes from the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Journal of Clinical Oncology, Vol. 42, Núm. 23, pp. 2790-2799
-
Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization
JHEP Reports, Vol. 6, Núm. 4
-
Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators
Journal of Prevention of Alzheimer's Disease
-
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
Journal of neurology, neurosurgery, and psychiatry, Vol. 95, Núm. 10, pp. 927-937
-
Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial
United European Gastroenterology Journal
-
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284
-
Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries
Heart and Lung, Vol. 68, pp. 131-144
-
Temporary mechanical circulatory support in infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials with 6-month follow-up
The Lancet, Vol. 404, Núm. 10457, pp. 1019-1028
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (Frontiers in Pharmacology, (2023), 14, (1124214), 10.3389/fphar.2023.1124214)
Frontiers in Pharmacology
-
Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes
The Lancet. Oncology, Vol. 24, Núm. 1, pp. 91-106
-
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
JHEP Reports, Vol. 5, Núm. 5
-
Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression
European Radiology, Vol. 33, Núm. 1, pp. 493-500
-
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692
-
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
Future oncology (London, England), Vol. 19, Núm. 38, pp. 2505-2516